Ibrance, a pill Pfizer sells for hormone-receptor-positive, HER2-negative breast cancer, is one of 15 drugs whose Medicare price the government negotiated down for 2027, cutting its monthly figure from a $15,741 list price to $7,871, a reduction of about 50 percent. The Centers for Medicare & Medicaid Services set that negotiated price as part of the program’s second cycle, effective January 1, 2027, alongside 14 other drugs treating cancer and chronic disease. The cut changes what CMS and Part D plans owe for the drug, but not automatically what a specific plan requires before covering it or what an enrollee owes at any given point in the year.
Ibrance’s approved use, and how far its list price has to fall
Ibrance’s active ingredient, palbociclib, treats hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer, the most common molecular subtype of the disease, taken alongside an aromatase inhibitor as initial therapy in postmenopausal women or with fulvestrant after the cancer progresses on an earlier hormone-based treatment. That combination approach, pairing a targeted pill with an existing hormone therapy, is part of why the drug’s own monthly price runs into five figures well before any government negotiation begins.
The Food and Drug Administration converted Ibrance’s initial accelerated approval to full approval and expanded that indication in 2017, according to Pfizer’s own account of that approval. Pfizer Oncology’s then-president, Liz Barrett, said at the time that more than 50,000 patients had already been prescribed Ibrance by roughly 9,800 physicians in the two years since the drug first reached the market, a scale that has only grown as the drug became a standard first-line option for this breast-cancer subtype.
A decade later, Ibrance’s list price has grown to $15,741 for a 30-day supply, the figure CMS used as the starting point for negotiation before arriving at the $7,871 maximum fair price that takes effect for Part D plans on January 1, 2027. That reduction is close to the median cut among the 15 drugs in this negotiation cycle, sitting between steeper reductions on drugs such as the diabetes injection Ozempic and shallower ones on drugs such as the mood stabilizer Vraylar.
What the price notice does not do: A negotiated monthly price for Ibrance tells a Part D plan what it owes CMS, not what a beneficiary owes once a plan’s own cost-sharing and coverage rules are applied over the course of a year. The Medicare Cost & Coverage Protection Kit’s medication and cost tracker exists for exactly that ongoing record. Log the Ibrance plan costs in The Medicare Cost & Coverage Protection Kit.
The negotiation math behind $7,871, not a Pfizer-set discount
CMS does not describe the negotiated price as a rebate or a coupon Pfizer offers voluntarily; the agency sets a legal ceiling under the Inflation Reduction Act’s negotiation authority, and the figure represents the outcome of a structured back-and-forth CMS conducted with Pfizer over the prior year rather than a number the company chose on its own. Pfizer could have declined to participate, but the Inflation Reduction Act attaches steep excise-tax penalties to that refusal, which is part of why every manufacturer contacted for this second cycle reached an agreed price rather than opting out.
That distinction matters for how the price functions going forward: a negotiated maximum fair price is a ceiling Part D plans and their pharmacy networks cannot exceed, not a price Pfizer can quietly raise again the following year without CMS renegotiating. CMS has said it intends to revisit negotiated prices periodically as the broader program continues rather than treating each cycle’s figure as a one-time, permanent number.
The negotiation applies specifically to Part D, the outpatient prescription-drug benefit; Ibrance administered or billed in a different setting, such as a hospital infusion suite, is not affected by this Part D maximum fair price, since palbociclib is an oral capsule most patients fill at a retail or mail-order pharmacy rather than receive by infusion.
Where the $2,000 cap already limits what a breast-cancer patient owes
Separately from the negotiated price, Medicare’s redesigned Part D benefit already caps a beneficiary’s annual out-of-pocket spending on covered drugs at $2,000, a threshold CMS set for calendar year 2025 under the program’s redesign instructions. A monthly Ibrance prescription at either price is expensive enough that most patients reach that cap early in a plan year, after which the negotiated price mostly affects what the government, the plan and Pfizer absorb between them rather than what shows up on the patient’s own statement.
CMS’s broader accounting of the second cycle, published in its November 25, 2025 announcement, put the combined savings across all 15 negotiated drugs at an estimated $12 billion, a roughly 44 percent reduction against what those drugs would otherwise have cost Part D, with about 5.3 million of the program’s 53 million enrollees having used one of the 15 drugs in 2024. Ibrance’s own share of that total is not broken out separately in the fact sheet, which reports the aggregate figure rather than a drug-by-drug savings breakdown.
Beyond the dollar figures, the negotiated price does not change the drug’s underlying safety profile or how a prescriber monitors a patient taking it. Ibrance still carries the same FDA-required warnings around low white blood cell counts and infection risk that applied at the higher list price, meaning the periodic bloodwork many oncologists order alongside a palbociclib prescription continues on the same schedule regardless of what CMS and Pfizer agreed to for 2027.
Tracking a breast-cancer prescription past the negotiated price
Ibrance’s negotiated price answers what CMS pays for the drug starting January 1, 2027, but it says nothing about the separate prior-authorization step many Part D plans already require before covering a specialty cancer drug, negotiated price or not, or about how close a given patient sits to the annual out-of-pocket threshold at any point in the year.
The Medicare Cost & Coverage Protection Kit lays out the prior-authorization appeal steps next to a medication and cost tracker, pairing the coverage hurdle with the ongoing spending record a breast-cancer prescription creates.
Read the appeal steps and start the cost tracker in The Medicare Cost & Coverage Protection Kit.
This article was researched and drafted with the assistance of AI and reviewed by The Money Overview editorial team.
